Co Diagnostics Stock Analysis

CODX
 Stock
  

USD 2.90  0.08  2.68%   

Co-Diagnostics price slide over the last few months could raise concerns from investors as the firm is trading at a share price of 2.90 on 140,147 in volume. The company management teams were not very successful in positioning the firm resources to exploit market volatility in November. However, diversifying your holdings with Co Diagnostics or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.34. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Co-Diagnostics partners.
Continue to Trending Equities.
  
The Co Diagnostics stock analysis report makes it easy to digest most publicly released information about Co Diagnostics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Co Diagnostics Stock analysis module also helps to analyze the Co Diagnostics price relationship with some important fundamental indicators such as market cap and management efficiency.

Co Diagnostics Stock Analysis Notes

About 21.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.71. Some equities with similar Price to Book (P/B) outperform the market in the long run. Co-Diagnostics had not issued any dividends in recent years. Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection andor analysis of nucleic acid molecules in the United States and internationally. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah. Co Diagnostics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 101 people. For more info on Co-Diagnostics please contact Dwight Egan at 801 438 1036 or go to https://www.codiagnostics.com.

Co-Diagnostics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Co Diagnostics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Co-Diagnostics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Co-Diagnostics generated a negative expected return over the last 90 days
Co-Diagnostics has high historical volatility and very poor performance
Latest headline from news.google.com: AXIM Biotechnologies Commercial Partner Versa Ophthalmics Highlights Benefits of AXIMs Eye Diagnostic Solutions - Marketscreener.com

Co-Diagnostics Upcoming and Recent Events

Earnings reports are used by Co Diagnostics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Co Diagnostics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report24th of March 2022
Next Financial Report12th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Co Diagnostics Largest EPS Surprises

Earnings surprises can significantly impact Co Diagnostics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2019-04-02
2019-03-31-0.13-0.15-0.0215 
2018-12-31
2018-12-31-0.13-0.15-0.0215 
2019-11-12
2019-09-30-0.07-0.1-0.0342 
View All Earnings Estimates

Co Diagnostics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Co Diagnostics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Co Diagnostics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Co-Diagnostics specific information freely available to individual and institutional investors to make a timely investment decision.
2nd of September 2022
Submission of Matters to a Vote of Security Holders
View
11th of August 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Results of Operations and Financial Condition
View
16th of June 2022
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
View
12th of May 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Results of Operations and Financial Condition
View
1st of April 2022
Financial Statements and Exhibits. Amendments to Articles of Incorporation or Bylaws; and/or Change in Fiscal Year
View
24th of March 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Results of Operations and Financial Condition
View
15th of March 2022
Other Events. Regulation FD Disclosure
View

Co Diagnostics Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 89.66 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Co Diagnostics's market, we take the total number of its shares issued and multiply it by Co Diagnostics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Co Diagnostics Profitablity

Co Diagnostics' profitability indicators refer to fundamental financial ratios that showcase Co Diagnostics' ability to generate income relative to its revenue or operating costs. If, let's say, Co Diagnostics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Co Diagnostics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Co Diagnostics' profitability requires more research than a typical breakdown of Co Diagnostics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 0.28 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.18 %, which suggests for every 100 dollars of sales, it generated a net operating income of 0.0.

Management Efficiency

The entity has return on total asset (ROA) of 0.0467 % which means that it generated profit of $0.0467 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 0.129 %, meaning that it created $0.129 on every $100 dollars invested by stockholders. Co Diagnostics management efficiency ratios could be used to measure how well co-diagnostics manages its routine affairs as well as how well it operates its assets and liabilities.
non Current Liabilities Total
13 M
interest Expense
45.6 K
total Operating Expenses
40.2 M
Beta
(0.64) 
common Stock Total Equity
33.8 K
selling And Marketing Expenses
13.4 M

Technical Drivers

As of the 7th of December, Co Diagnostics owns the Coefficient Of Variation of (3,895), standard deviation of 3.31, and Market Risk Adjusted Performance of (0.07). Co-Diagnostics technical analysis gives you the methodology to make use of past data patterns to determine a pattern that approximates the direction of the firm's future prices. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume patterns, or the prices will eventually revert. We were able to break down nineteen technical drivers for Co Diagnostics, which can be compared to its peers in the sector. Please confirm Co-Diagnostics standard deviation, as well as the relationship between the maximum drawdown and expected short fall to decide if Co-Diagnostics is priced more or less accurately, providing market reflects its prevailing price of 2.9 per share. Please also double-check Co Diagnostics total risk alpha, which is currently at (0.24) to validate the company can sustain itself in the future.

Co-Diagnostics Price Movement Analysis

Execute Study
The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Co Diagnostics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Co-Diagnostics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
.

Co-Diagnostics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Co Diagnostics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Co Diagnostics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Co Diagnostics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Eugene Durenard over a week ago via Macroaxis 
Acquisition by Eugene Durenard of 11667 shares of Co Diagnostics subject to Rule 16b-3
Reed Benson over two months ago via Macroaxis 
Payment of 1414 shares by Reed Benson of Co Diagnostics subject to Rule 16b-3
Eugene Durenard over three months ago via Macroaxis 
Acquisition by Eugene Durenard of 70000 shares of Co Diagnostics subject to Rule 16b-3
Brown Brian Lee over six months ago via Macroaxis 
Acquisition by Brown Brian Lee of 225000 shares of Co Diagnostics subject to Rule 16b-3
Brown Brian Lee over six months ago via Macroaxis 
Exercise or conversion by Brown Brian Lee of 21666 shares of Co Diagnostics subject to Rule 16b-3
Richard Serbin over six months ago via Macroaxis 
Sale by Richard Serbin of 17000 shares of Co Diagnostics
Eugene Durenard over six months ago via Macroaxis 
Exercise or conversion by Eugene Durenard of 12500 shares of Co Diagnostics subject to Rule 16b-3
Brown Brian Lee over a year ago via Macroaxis 
Exercise or conversion by Brown Brian Lee of 21667 shares of Co Diagnostics subject to Rule 16b-3
Eugene Durenard over a year ago via Macroaxis 
Sale by Eugene Durenard of 2000 shares of Co Diagnostics
Reed Benson over a year ago via Macroaxis 
Exercise or conversion by Reed Benson of 100000 shares of Co Diagnostics subject to Rule 16b-3
Brown Brian Lee over a year ago via Macroaxis 
Acquisition by Brown Brian Lee of 100000 shares of Co Diagnostics subject to Rule 16b-3
Brown Brian Lee over a year ago via Macroaxis 
Exercise or conversion by Brown Brian Lee of 5000 shares of Co Diagnostics subject to Rule 16b-3

Co Diagnostics Technical and Predictive Indicators

Co Diagnostics Forecast Models

Co Diagnostics time-series forecasting models is one of many Co Diagnostics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Co Diagnostics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Co Diagnostics Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Co Diagnostics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Co Diagnostics shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Co Diagnostics. By using and applying Co Diagnostics Stock analysis, traders can create a robust methodology for identifying Co Diagnostics entry and exit points for their positions.
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection andor analysis of nucleic acid molecules in the United States and internationally. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah. Co Diagnostics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 101 people.

Current Co Diagnostics Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Co Diagnostics analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Co Diagnostics analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
22.0Buy2Odds
Co-Diagnostics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Co Diagnostics analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Co Diagnostics stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Co-Diagnostics, talking to its executives and customers, or listening to Co Diagnostics conference calls.
Co Diagnostics Analyst Advice Details

Co Diagnostics Stock Analysis Indicators

Co-Diagnostics stock analysis indicators help investors evaluate how Co Diagnostics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Co Diagnostics shares will generate the highest return on investment. By understating and applying Co Diagnostics stock analysis, traders can identify Co Diagnostics position entry and exit signals to maximize returns.
Begin Period Cash Flow42976713.00
Logo U R LimglogosUSCODX.png
Common Stock Shares Outstanding29903686.00
Total Stockholder Equity134475098.00
DescriptionCo-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection andor analysis of nucleic acid molecules in the United Sta
Total Cashflows From Investing Activities4098699.00
Tax Provision8977231.00
Quarterly Earnings Growth Y O Y0.308
Property Plant And Equipment Net1933216.00
Retained Earnings54169279.00
Cash And Short Term Investments89862500.00
Retained Earnings Total Equity54169279.00
Cash88607234.00
CodeCODX
Accounts Payable607506.00
Net Debt-88607234.00
50 Day M A3.3095
Total Current Liabilities12597550.00
Currency CodeUSD
Other Operating Expenses51820651.00
Non Current Assets Total44914987.00
Forward Price Earnings16
Common Stock Total Equity33820.00
Non Currrent Assets Other75000.00
Continue to Trending Equities. Note that the Co-Diagnostics information on this page should be used as a complementary analysis to other Co Diagnostics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Complementary Tools for Co Diagnostics Stock analysis

When running Co-Diagnostics price analysis, check to measure Co Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Co Diagnostics is operating at the current time. Most of Co Diagnostics' value examination focuses on studying past and present price action to predict the probability of Co Diagnostics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Co Diagnostics' price. Additionally, you may evaluate how the addition of Co Diagnostics to your portfolios can decrease your overall portfolio volatility.
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Is Co Diagnostics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Co Diagnostics. If investors know Co Diagnostics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Co Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
0.308
Market Capitalization
89.7 M
Quarterly Revenue Growth YOY
(0.83) 
Return On Assets
0.0467
Return On Equity
0.129
The market value of Co-Diagnostics is measured differently than its book value, which is the value of Co Diagnostics that is recorded on the company's balance sheet. Investors also form their own opinion of Co Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Co Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Co Diagnostics' market value can be influenced by many factors that don't directly affect Co Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Co Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine Co Diagnostics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Co Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.